

2015 Supplemental Antibiogram for the University of Washington and Harborview Medical Centers

Organism (% susceptible)	Maximum # of isolates tested		Ceftriaxone		Clindamycin		Erythromycin		Levofloxacin ^c		Moxifloxacin		Penicillin		Vancomycin	
	H	U	H	U	H	U	H	U	H	U	H	U	H	U	H	U
<i>Streptococcus agalactiae</i> (Group B)	31	40	100	100	55 ^d	67	48	49		100	100 ^a	100 ^a	100	100	100	100
<i>Streptococcus milleri</i> group	99	80	100	100	73 ^d	86	73	71		100	99 ^b	100 ^b	93	79	100	100
<i>Streptococcus pyogenes</i> (Group A)	99		100		66 ^d		69				100 ^a		100		100	

Blank cells = insufficient data or drug is not tested. H = HMC; U = UWMC.

- ^a No CLSI breakpoints are available for moxifloxacin, therefore EUCAST breakpoints for *Streptococcus* Groups A, B, C, and G (≤ 0.50 $\mu\text{g/mL}$ susceptible and ≥ 1.0 $\mu\text{g/mL}$ resistant) were used to determine % susceptible.
- ^b Currently there are no existing breakpoints for moxifloxacin. However, a provisional susceptible breakpoint of ≤ 1.0 $\mu\text{g/mL}$ has been suggested for *S. pneumoniae* and could be considered applicable to viridans group streptococci (Andrews, et al. 1999, PMID 10590284).
- ^c Current susceptibility methods may fail to detect single-step mutations conferring low-level levofloxacin resistance.
- ^d At HMC 29% of *Streptococcus pyogenes* (Group A) exhibited inducible clindamycin resistance, 19% of *Streptococcus agalactiae* (Group B) exhibited inducible clindamycin resistance, and 2% of *Streptococcus milleri* group exhibited inducible clindamycin resistance.

Organism (% susceptible)	Maximum # of isolates tested		Amphotericin B		Fluconazole		Micafungin		Voriconazole	
	H	U	H	U	H	U	H	U	H	U
<i>Candida albicans</i>	60	54	100	100	95	100	100	100	98	100
<i>Candida glabrata</i>	33	39	100 ^a	97	15 ^b	21 ^b	100 ^a	92		

Blank cells = insufficient data or drug was not tested. H = HMC; U = UWMC.

- ^a An insufficient number of isolates were tested at the HMC in 2015 to be statistically significant. Additional 2014 data were included in this analysis.
- ^b NOTE: Some *Candida glabrata* isolates exhibit dose-dependent susceptibility against Fluconazole. Current CLSI interpretive breakpoints are not reflective of full susceptibility at all antibiotic dosages and therefore may not predict clinical efficacy. An ID consult is recommended.